Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leurs, P. B.
Right arrow Articles by Wolffenbuttel, B. H. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leurs, P. B.
Right arrow Articles by Wolffenbuttel, B. H. R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 25:1340-1345, 2002
© 2002 by the American Diabetes Association, Inc.

Epidemiology/Health Services/Psychosocial Research
Original Article

Tissue Factor Pathway Inhibitor and Other Endothelium-Dependent Hemostatic Factors in Elderly Individuals With Normal or Impaired Glucose Tolerance and Type 2 Diabetes

Paul B. Leurs, MD, PHD1, Ronald P. Stolk, MD, PHD2, Karly Hamulyak, MD, PHD3, René van Oerle3, Diederick E. Grobbee, MD, PHD2 and Bruce H. R. Wolffenbuttel, MD, PHD1

1 Department of Endocrinology, University Hospital, Maastricht, the Netherlands
2 Departments of Epidemiology and Biostatistics, Erasmus University Medical School, Rotterdam, the Netherlands
3 Department of Hematology, University Hospital, Maastricht, the Netherlands


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 
OBJECTIVE—Impaired glucose tolerance (IGT) is believed to be a prediabetic phase that precedes the development of type 2 diabetes. In elderly subjects, IGT and diabetes are both independently associated with the occurrence of cardiovascular disease. Endothelial damage precedes atherosclerotic changes of the vascular wall. Therefore, several markers of endothelial dysfunction were examined in elderly subjects with IGT and elderly patients with type 2 diabetes.

RESEARCH DESIGN AND METHODS—Von Willebrand factor (vWF), tissue plasminogen activator (t-PA), plasminogen activator inhibitor type-1 (PAI-1), and thrombomodulin were studied as markers of endothelial dysfunction in a population-based study of elderly subjects with normal glucose tolerance (NGT) or IGT and type 2 diabetes. In addition to these endothelium-dependent factors, we also investigated tissue factor pathway inhibitor (TFPI) activity in relation to metabolic parameters and cardiovascular risk factors.

RESULTS—All data were adjusted for age. Increased levels of vWF antigen, t-PA antigen, and PAI-1 activity were seen in the IGT and diabetic group compared with the NGT group. TFPI activity and thrombomodulin levels were increased in all elderly subjects, and no differences were seen between the groups. There was a positive association between HbA1c and TFPI activity and vWF antigen. Fasting blood glucose levels correlated with vWF antigen, t-PA antigen, and PAI-1 activity, whereas urine albumin excretion correlated with TFPI activity, vWF antigen, and PAI-1 activity. Serum insulin levels correlated strongly not only with vWF antigen and t-PA antigen but also with PAI-1 activity. This correlation did not change after further adjustment for serum glucose and HbA1c, which may suggest that in the elderly subjects, impaired fibrinolysis is probably associated with insulin resistance. There were no associations between the endothelium-dependent hemostatic factors and lipids, except for a negative correlation between HDL cholesterol and thrombomodulin.

CONCLUSIONS—In elderly subjects with IGT, several endothelium-dependent hemostatic factors are already consistently increased, indicating endothelial damage in this stage.

Abbreviations: CV, coefficient of variation • ELISA, enzyme linked immunosorbent assay • F1 + 2, prothrombin fragments 1 + 2 • IGT, impaired glucose tolerance • NGT, normal glucose tolerance • PAI-1, plasminogen activator inhibitor type-1 • TFPI, tissue factor pathway inhibitor • t-PA, tissue-plasminogen activator • vWF, von Willebrand factor


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 
The state of impaired glucose tolerance (IGT) is considered a transitional phase to the development of type 2 diabetes. The prevalence of IGT and type 2 diabetes is increasing with age (1–3). Aging itself is not the only risk factor for atherosclerosis; IGT and diabetes are also independently associated with the occurrence of cardiovascular disease (4,5). Several factors contribute to the development of cardiovascular disease in diabetic and nondiabetic subjects, such as dyslipidemia, (micro)albuminuria, and hypertension (6–12). Hyperinsulinemia as an independent risk factor is controversial (13). It has been shown that endothelial damage precedes atherosclerotic changes of the vascular wall. Therefore, several markers of endothelial (dys)function, such as von Willebrand factor (vWF), tissue plasminogen activator (t-PA), plasminogen activator inhibitor type-1 (PAI-1), and thrombomodulin have been studied in the past to assess whether they can predict the risk of developing cardiovascular disease (14–17). Recently, we and others have demonstrated increased tissue factor pathway inhibitor (TFPI) activity in patients with diabetes (18,19). This seems to be particularly true in patients with diabetes and microalbuminuria (19,20). Because TFPI is mainly produced by and bound to the vascular endothelium, possibly by glycosaminoglycans (21), these data suggest that TFPI may also reflect endothelial (dys)function. In addition, TFPI is partly associated with lipoproteins (22,23). In a population-based study, we studied TFPI activity and other endothelium-dependent factors in elderly subjects with NGT, IGT, and type 2 diabetes.


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
RESULTS
 CONCLUSIONS
 References
 
Subjects
The study was conducted in participants of the Rotterdam Study, a population-based prospective cohort study of determinants of chronic disabling diseases in the elderly (24). The baseline examinations were conducted between 1990 and 1993 and included 7,983 subjects (response rate 78%). Informed consent was obtained from all subjects, and the study was approved by the medical ethics committee of the Erasmus University Medical School. The participants were evaluated with respect to microvascular and macrovascular complications (history, physical examination, urinary albumin excretion, and electrocardiography), diabetes control, and lipid profile. Grade of retinopathy was assessed by an ophthalmologist by means of funduscopic examination. During the first follow-up examination of the Rotterdam Study in 1993–1994, a sample of participants aged 55–75 years at baseline was invited to participate in an additional diabetes examination, including an oral glucose tolerance test. The overall response rate for the follow-up examination was 90%; 1,107 subjects participated in the diabetes study. The present study population consists of a random sample of 144 men and women who were divided according to their glucose tolerance at follow-up, using the World Health Organization (WHO) criteria, into a group with NGT, a group with IGT, and a group with diabetes. With the oral glucose tolerance test, 39 cases of newly diagnosed diabetes were identified. The subjects did not use medication, which could influence hemostasis. The characteristics of the subjects studied are shown in Table 1.


View this table:
[in this window]
[in a new window]
  		Table 1— Characteristics of subjects with normal and IGT and type 2 diabetes

 
Methods
Fasting blood samples for this cross-sectional survey were collected in tubes containing sodium citrate 3.25% (dilution 1:10) for determining TFPI activity, vWF antigen, thrombomodulin, t-PA antigen and PAI-1 activity, HbA1c, and lipid profile at baseline.

TFPI activity was measured using the chromogenic substrate assay according to Sandset after pretreatment with polybrene (expressed in percent with regard to standardized TFPI activity, measured in a plasma pool obtained from 45 healthy donors with a mean age 36 ± 5 years; coefficient of variation [CV] 7.4% at 100% level in our laboratory). In vivo thrombin formation was assessed by determination of prothrombin fragments 1 + 2 (F1 + 2) using enzyme-linked immunosorbent assay (ELISA; Enzygnost Behring, Marburg, Germany; intra-assay CV 5–7 ± 5%, interassay CV 6–13%). Plasma levels of vWF antigen were determined by an ELISA method using rabbit anti-human vWF (Dako, Denmark; CV 7%, normal range 60–180%). Thrombomodulin (Diagnostica Stago, France; CV 8%, mean 24 ng/ml) and t-PA antigen (Innogenetics, Belgium; CV 7%, normal range 1.3–10.4 ng/ml, mean 4.1 ± 2.4 ng/ml) were measured by enzyme immunoassay. PAI-1 activity was photometrically measured (Kabi Diagnostica, Sweden; intra-assay CV 6%, normal range 1–20 AU/ml, median 8 AU/ml). HbA1c was measured by high-performance liquid chromatography (Diamat; Bio-Rad, Richmond, CA). Serum total cholesterol, HDL cholesterol, and triglyceride levels were determined with enzymatic methods (Unimate 5 and 7; Roche, Basel, Switzerland), and apolipoprotein A1 and apolipoprotein B were measured with immunoturbidimetry (Uni-kit; Roche). An enzymatic hexokinase method (Unimate 5; Roche) was used for measuring serum glucose concentrations. Serum free insulin was measured with a double antibody radioimmunoassay after pretreatment with polyethylene glycol (Pharmacia Diagnostics, Uppsala, Sweden; within-assay CV 3.4–6.1% in the range of 3–50 mU/l). For determination of urinary albumin, an immunoturbidimetric technique was applied (Uni-kit; Roche; interassay CV 3%).

All data are expressed as means ± SD or as medians and ranges when not normally distributed. For comparing more than two groups, ANOVA with Student-Newman-Keuls correction for multiple comparisons was used. If data were not normally distributed, the Kruskall-Wallis ANOVA was applied. Categorical variables were analyzed by the {chi}2 test. Multivariate logistic regression analyses (based on the maximum-likelihood method) were used to investigate the association of TFPI activity with other endothelium-dependent parameters and cardiovascular risk factors. P values <=0.05 were considered statistically significant.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
CONCLUSIONS
 References
 
There were no statistically significant differences in sex among the NGT, IGT, and diabetes groups (Table 1). The mean age, BMI, and systolic blood pressure of the NGT subjects were significantly lower than in the subjects with IGT and diabetes. The diastolic blood pressure was significantly higher in the IGT subjects than in the NGT subjects. Serum insulin levels were higher in the IGT and diabetes groups compared with the NGT group. No differences in serum insulin levels were found between the IGT and diabetic subjects. The lipid profile was similar in the three groups. Because TFPI activity, t-PA antigen, PAI-1 activity, and vWF antigen increase with age, the results were adjusted for age (21,25,26). Smoking did not influence the results. Compared with the NGT subjects, vWF antigen, t-PA antigen, and PAI-1 activity were all significantly higher in the IGT and diabetic subjects (Table 2). TFPI activity was increased in all groups as compared with the younger healthy volunteers, from which the standardized plasma pool was obtained. The TFPI activity was highest in the patients with diabetes, although it was higher in the IGT group compared with the NGT group. However, the differences were small and not statistically significant. Thrombomodulin levels showed the same pattern. Albumin excretion rate was not different among the three groups. In total, 17 subjects had microalbuminuria, of which four had NGT, four had IGT, and nine had diabetes. One patient with diabetes had macroalbuminuria. Also, with regard to the procoagulant state, as measured by the prothrombin F1 + 2 fragments, the three groups did not differ.


View this table:
[in this window]
[in a new window]
  		Table 2— Hemostatic endothelium-dependent factors and albuminuria by categories of glucose intolerance

 
When correlating the different hemostatic endothelium-dependent factors with the metabolic parameters, it seemed that TFPI activity, vWF antigen, and PAI-1 activity were significantly positively correlated with HbA1c (Table 3). However, these correlations were moderate. There was a correlation between fasting blood glucose and vWF antigen, t-PA antigen, and PAI-1 activity, whereas serum insulin was strongly correlated with vWF antigen (r = 0.34), t-PA antigen (r = 0.60), and PAI-1 activity (r = 0.47). The strong relation between insulin levels and PAI-1 activity and t-PA antigen remained after further adjustment for serum glucose and HbA1c. Total cholesterol was only correlated with PAI-1 activity. In addition, there was a negative correlation between HDL cholesterol and t-PA antigen, PAI-1 activity, and thrombomodulin. PAI-1 activity and t-PA antigen were positively associated with triglycerides. The partial correlation coefficients between the various endothelial-dependent factors and cardiovascular risk factors are shown in Table 4. In addition to TFPI activity, vWF antigen and PAI-1 activity were positively correlated with the urine albumin excretion. Table 5 shows the interrelationships between the endothelium-dependent factors. PAI-1 activity and thrombomodulin were associated with vWF antigen and t-PA antigen, whereas the latter was also correlated with vWF antigen. There seemed to be a borderline correlation between TFPI activity and vWF antigen and PAI-1 activity.


View this table:
[in this window]
[in a new window]
  		Table 3— Correlations between endothelium-dependent factors and metabolic parameters.

 

View this table:
[in this window]
[in a new window]
  		Table 4— Correlations between endothelium-dependent factors and cardiovascular risk factors

 

View this table:
[in this window]
[in a new window]
  		Table 5— Correlations between endothelium-dependent factors

 

   CONCLUSIONS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
References
 
In the present study, elderly subjects with IGT were shown to have already increased levels of several endothelium-dependent hemostatic factors, indicating endothelial damage in this stage. Atherosclerotic change of the arterial vascular bed is one of the main events of aging. Disturbances in glucose metabolism accelerate this process of atherosclerosis. Because endothelial damage plays a central role in the pathogenesis of cardiovascular disease, one may thereby assume that in subjects with a disturbed glucose metabolism, more vascular endothelial dysfunction is present in comparison with age-matched healthy control subjects. More vascular dysfunction may thereby be reflected by higher levels of circulating endothelium-derived factors.

We observed significantly increased levels of vWF antigen, t-PA antigen, and PAI-1 activity in the IGT group as well as in the diabetes group as compared with the NGT group. This confirms earlier reports in which it was also suggested that these alterations resulted from damage of endothelial cells (27). Because there were no differences between the IGT and diabetes groups, the increases in levels of vWF antigen, t-PA antigen, and PAI-1 activity could suggest that part of the endothelial damage may already occur in the prediabetic phase. This may explain the reported increased incidence of cardiovascular disease in these two groups. It is known that the levels of vWF antigen, t-PA antigen, and PAI-1 activity are influenced by glucose metabolism (28–30). Compared with the NGT group, fasting glucose was highest in the IGT and diabetes groups, whereas HbA1c was significantly higher in the subjects with type 2 diabetes. Correlation analysis showed a positive association not only between HbA1c and vWF antigen but also between fasting blood glucose and vWF antigen, t-PA antigen, and PAI-1 activity. In addition, serum insulin correlated also with these three endothelial hemostatic factors. In particular, there was a strong relation between insulin levels and PAI-1 activity and t-PA antigen, which remained after further adjustment for serum glucose and HbA1c. These findings suggest that higher insulin levels, and therefore probably insulin resistance, are associated with impaired fibrinolysis in elderly subjects with or without diabetes.

Thrombomodulin levels were increased in the three groups, but no differences between the groups could be demonstrated. However, thrombomodulin did not correlate with the risk factors or any of the metabolic parameters, with the exception of HDL cholesterol. This is in contrast to an earlier report in which no correlation between lipids and thrombomodulin was found (31), whereas others had the same findings (32).

Although we found a slightly higher level of TFPI activity in the IGT and diabetes groups, this difference was not statistically significant. However, we were able to demonstrate a significant association between TFPI activity and HbA1c. This is in agreement with the findings of Kario et al. (19), who also found increased TFPI antigen levels in patients with type 2 diabetes, especially those with overt albuminuria, compared with healthy control subjects. In the present study, a significant correlation between TFPI activity and the albumin excretion rate could also be demonstrated. Because microalbuminuria is a sign of generalized angiopathy, TFPI may be a marker of this condition. The same correlation could also be demonstrated between albuminuria and vWF antigen and PAI-1 activity. However, in comparison with type 1 diabetes, type 2 diabetes is considered a different disease regarding vascular complications. Although type 2 diabetes is characterized by the occurrence of macrovascular complications, in patients with type 1 diabetes, mainly microvascular complications are observed before macrovascular abnormalities occur. TFPI expression is restricted to the endothelium of the microvasculature and is not believed to be synthesized by the endothelium of larger vessels (33). This may explain, in part, why no significant differences between the diabetes and NGT groups were found in the present study. In addition, the elderly subjects in the present study population seemed to be relatively free of cardiovascular disease. In addition, only a total of 17 subjects in all three groups had microalbuminuria, whereas one subject with diabetes had macroalbuminuria. The presence of extensively generalized angiopathy would therefore be less likely. Others found increased levels of TFPI only in patients with type 2 diabetes and overt albuminuria (19).

It is widely accepted that in patients with diabetes, a procoagulant state can be found (34,35). Because TFPI is a coagulation inhibitor, one may suggest that TFPI activity is influenced by this procoagulant state. In an earlier study of patients with type 1 diabetes, no correlation between a procoagulant status and TFPI activity could be demonstrated (20). In the present study, we were unable to show a difference in procoagulation, as measured by the prothrombin fragments 1 + 2 (F1 + 2), between the three groups. There was also no significant correlation between TFPI activity and the F1 + 2 fragments in this patient population. Others were also unable to demonstrate a correlation between TFPI and factor VIIa levels (19). In addition, we could not find a relation between F1 + 2 and the other endothelial hemostatic factors.

Dyslipidemia is a well-recognized risk factor for cardiovascular disease in subjects with IGT and type 2 diabetes (4,6). Because TFPI in plasma is mainly associated with lipoproteins, especially with LDL and HDL (22,23), TFPI activity could be influenced by the levels of lipoproteins. The levels of lipoproteins were similar in the three groups, and no significant relationship between TFPI activity and lipids was found. This is in agreement with our earlier report of patients with type 1 diabetes, whereas others have found a positive relation in nondiabetic hypercholesterolemic subjects (18,36). Only PAI-1 activity was associated with total cholesterol, whereas there was a negative correlation between HDL cholesterol and t-PA antigen, PAI-1 activity, and thrombomodulin.

The endothelium-dependent factors are also known to be affected by blood pressure (37–39). The systolic blood pressure was higher in the subjects with IGT and diabetes, whereas the diastolic blood pressure was higher in the IGT group. However, the systolic and diastolic blood pressures were only positively correlated with PAI-1 activity. Obesity is another well-known risk factor for cardiovascular complications (40). The BMI was higher in the IGT and diabetes groups. In addition, a significant positive correlation between BMI and t-PA antigen, PAI-1 activity, and vWF antigen could be demonstrated. This is in concordance with the findings of earlier studies (41–43). In contrast to Vambergue et al. (44), we could not find a correlation between BMI and TFPI activity.

We concluded that several hemostatic endothelium-dependent factors are already increased in elderly subjects, relatively free of cardiovascular disease, with IGT, which is believed to precede the development of type 2 diabetes. This seems to be especially true for vWF antigen, t-PA antigen, and PAI-1 activity. TFPI activity and thrombomodulin levels were increased in all elderly subjects with NGT or IGT and type 2 diabetes, but there were no differences among the groups. However, the positive correlation between HbA1c and TFPI activity may indicate an influence of overall glycemic control on TFPI activity. Because of the strong correlation between PAI-1 activity and t-PA antigen and insulin levels after adjustment for glucose and HbA1c, one may hypothesize that endothelial dysfunction may precede insulin resistance in elderly individuals.


   Footnotes
 
Address correspondence and reprint requests to Paul B. Leurs, MD, PhD, Department of Internal Medicine, Oosterschelde Hospital, P.O. Box 106, 4460 BB Goes, the Netherlands. E-mail: pleurs{at}soz.nl.

Received for publication 4 April 2002 and accepted in revised form 29 April 2002.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.


   References
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 

  1. Kannel WB, Garrison RJ, Wilson PWF: Obesity and nutrition in elderly diabetic patients. Am J Med 80 (Suppl. 5A):22–30, 1986[Medline]
  2. Agner E, Thorsteinsson B, Eriksen M: Impaired glucose tolerance and diabetes mellitus in elderly subjects. Diabetes Care 5:600–604, 1982[Abstract]
  3. Harris MI, Hadden WC, Knowler WC, Bennett PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20–74 yr. Diabetes 36:523–534, 1987[Abstract]
  4. Mykkänen L, Laakso M, Pyörälä K: Asymptomatic hyperglycemia and atherosclerosic vascular disease in the elderly. Diabetes Care 15:1020–1030, 1992[Abstract]
  5. Wingard DL, Barrett-Connor EL, Scheidt-Nave C, McPhillips JB: Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. Diabetes Care 16:1022–1025, 1993[Abstract]
  6. Parving HH, Gall MA, Nielsen FS: Dyslipidaemia and cardiovascular disease in non-insulin-dependent diabetic patients with and without diabetic nephropathy. J Intern Med 736 (Suppl.):89–94, 1994
  7. Schmitz A, Vaeth M, Mogensen CE: Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM. Diabetologia 37:1251–1258, 1994[Medline]
  8. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44:1303–1309, 1995[Abstract]
  9. MacLeod JM, Lutale J, Marshall SM: Albumin excretion and vascular deaths in NIDDM. Diabetologia 38:610–616, 1995[Medline]
  10. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J: A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 16:996–1003, 1993[Abstract]
  11. Mattock MB, Morrish NJ, Viberti G, Keen H, Fritzgerald AP, Jackson G: Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41:736–741, 1992[Abstract]
  12. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE: Microalbuminuria as a predictor of increased mortality in elderly people. BMJ 300:297–300, 1990
  13. Kuusisto J, Mykkanen L, Pyorala K, Laakso M: Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation 91:831–837, 1995[Abstract/Free Full Text]
  14. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ: Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340:319–323, 1992[Medline]
  15. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G: High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98:2241–2247, 1998[Abstract/Free Full Text]
  16. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D’Agostino RB, Wilson PW: Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 283:221–228, 2000[Abstract/Free Full Text]
  17. Lee AJ, MacGregor AS, Hau CM, Price JF, Rumley A, Lowe GD, Fowkes FG: The role of haematological factors in diabetic arterial disease: the Edinburgh artery study. Br J Haematol 105:648–654, 1999[Medline]
  18. Leurs PB, van Oerle R, Hamulyak K, Wolffenbuttel BHR: Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes 44:80–84, 1995[Abstract]
  19. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T: Activation of tissue factor-induced coagulation and endothelial dysfunction in non-insulin dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 15:1114–1120, 1995[Abstract/Free Full Text]
  20. Leurs PB, van Oerle R, Wolffenbuttel BHR, Hamulyak K: Increased tissue factor inhibitor and coagulation in patients with insulin-dependent diabetes mellitus. Thromb Haemost 77:472–476, 1997[Medline]
  21. Lindahl AK, Sandset PM, Abildgaard U: The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 3:439–449, 1992[Medline]
  22. Novotny WF, Girard TJ, Miletich JP, Broze GJ: Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 264:18832–18837, 1989[Abstract/Free Full Text]
  23. Lesnik P, Vonica A, Guerin M, Moreau M, Chapman MJ: Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Aterioscler Thromb 13:1066–1075, 1993[Abstract/Free Full Text]
  24. Hofman A, Grobbee DE, de Jong PTVM, van de Ouweland FA: Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 7:403–422, 1991[Medline]
  25. Haverkate F, Thompson SG, Duckert F: Haemostasis factors in angina pectoris; relation to gender, age and acute-phase reaction. Thromb Haemost 73:561–567, 1995[Medline]
  26. Ariëns RAS, Coppola R, Potenza I, Mannucci PM: The increase with age of the components of tissue factor coagulation pathway is gender-dependent. Blood Coagul Fibrinolysis 6:433–437, 1995[Medline]
  27. Collier A, Rumley A, Rumley AG, Paterson JR, Leach JP, Lowe GDO, Small M: Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 41:909–913, 1992[Abstract]
  28. Gonzalez J, Colwell A, Sarji KE, Nair RMG, Sagel J: Effect of metabolic control with insulin on plasma von Willebrand factor activity (VIII R:vWF) in diabetes mellitus. Thromb Res 17:261–266, 1980[Medline]
  29. Juhan-Vague I, Vague P, Poisson C, Aillaud MF, Mendez C, Collen D: Effect of 24 hours of normoglycaemia on tissue-type plasminogen activator plasma levels in insulin-dependent diabetes. Thromb Haemost 51:97–98, 1984[Medline]
  30. Bahru Y, Kesteven P, Alberti KG, Walker M: Decreased plasminogen activator inhibitor-1 activity in newly diagnosed type 2 diabetic patients following dietary modification. Diabet Med 10:802–806, 1993[Medline]
  31. Nilsson TK, Hellsten G, Amiral J: Plasma thrombomodulin concentrations in relation to cardiovascular risk factors in a population sample. Blood Coagul Fibrinolysis 4:455–458, 1993[Medline]
  32. Aso Y, Fujiwara Y, Tayama K, Takanashi K, Inukai T, Takemura Y: Relationship between plasma soluble thrombomodulin levels and insulin resistance syndrome in type 2 diabetes: a comparison with von Willebrand factor. Exp Clin Endocrinol Diabetes 109:210–216, 2001[Medline]
  33. Osterud B, Bajaj MS, Bajaj SP, on behalf of the Subcommittee on Tissue Factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH: Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. Thromb Haemost 73:873–875, 1995[Medline]
  34. Ostermann H, van de Loo J: Factors of the hemostatic system in diabetic patients: a survey of controlled studies. Haemostasis 16:386–416, 1986[Medline]
  35. Carmassi F, Morale M, Pucetti R, De Negri F, Monzani F, Navalesi R, Mariani G: Coagulation and fibrinolytic system impairment in insulin-dependent diabetes mellitus. Thromb Res 67:643–654, 1992[Medline]
  36. Sandset PM, Lund H, Norseth J, Abildgaard U, Ose L: Treatment with hydroxymethylglytaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb 11:138–145, 1991[Abstract/Free Full Text]
  37. Gleerup G, Winther K: Decreased fibrinolytic activity and increased platelet function in hypertension: possible influence of calcium antagonism. Am J Hypertens 4:168S–171S, 1991[Medline]
  38. Landin K, Tengborn L, Smith U: Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 227:273–278, 1990[Medline]
  39. Blann AD, Naqvi T, Waite M, McCollum CN: Von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 7:107–111, 1993[Medline]
  40. Hubert HB, Feinleib M, McNamara P, Castelli WP: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67:968–977, 1983[Abstract/Free Full Text]
  41. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE: The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42:945–949, 1993[Medline]
  42. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U: Abdominal obesity is associated with impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 39:1044–1048, 1990[Medline]
  43. Blann AD, Bushell D, Davies A, Faragher EB, Miller JP, McCollum CN: Von Willebrand factor, the endothelium and obesity. Int J Obesity 17:723–725, 1993
  44. Vambergue A, Rugeri L, Gaveriaux V, Devos P, Martin A, Fermon O, Fontaine P, Jude B: Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age. Thromb Res 101:367–375, 2001[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
R. L.C. Hoo, W.S. Chow, M.H. Yau, A. Xu, A. W.K. Tso, H.F. Tse, C. H.Y. Fong, S. Tam, L. Chan, and K. S.L. Lam
Adiponectin Mediates the Suppressive Effect of Rosiglitazone on Plasminogen Activator Inhibitor-1 Production
Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2777 - 2782.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. de Jager, J. M. Dekker, A. Kooy, P. J. Kostense, G. Nijpels, R. J. Heine, L. M. Bouter, and C. D.A. Stehouwer
Endothelial Dysfunction and Low-Grade Inflammation Explain Much of the Excess Cardiovascular Mortality in Individuals With Type 2 Diabetes: The Hoorn Study
Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 1086 - 1093.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. M. Kanaya, C. Wassel Fyr, E. Vittinghoff, T. B. Harris, S. W. Park, B. H. Goodpaster, F. Tylavsky, and S. R. Cummings
Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1.
Arch Intern Med, February 13, 2006; 166(3): 350 - 356.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leurs, P. B.
Right arrow Articles by Wolffenbuttel, B. H. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leurs, P. B.
Right arrow Articles by Wolffenbuttel, B. H. R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum